| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Journal of Korean Neurosurgical Society 2009;46(1): 45-51.
doi: https://doi.org/10.3340/jkns.2009.46.1.45
The Effect of Risedronate on Posterior Lateral Spinal Fusion in a Rat Model.
Ali Riza Gezici, Ruchan Ergun, Kamil Gurel, Fahri Yilmaz, Onder Okay, Omer Bozdogan
1Department of Neurosurgery, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey. geziciar@gmail.com
2Department of Radiology, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey.
3Department of Pathology, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey.
4Clinic of Neurosurgery, Ankara Numune Hospital, Ankara, Turkey.
5Department of Biology, Faculty of Arts and Sciences, Abant Izzet Baysal University, Bolu, Turkey.
ABSTRACT
OBJECTIVE
To evaluate the potential effects of risedronate (RIS) which shows a higher anti-resorptive effect among bisphosphonates, after a posterolateral lumbar intertransverse process spinal fusion using both autograft and allograft in a rat model. METHODS: A totoal of 28 Sprague-Dawley rats were randomized into 2 study groups. A posterolateral lumbar intertransverse process spinal fusion was peformed using both autograft and allograft in a rat model. Group I (control) received 0.1 mL of steril saline (placebo) and Group II (treatment) received risedronate, equivalent to human dose (10 microgram/kg/week) for 10-weeks period. RESULTS: The fusion rates as determined by manual palpation were 69% in the group I and 46% in the group II (p = 0.251). According to radiographic score, the spinal segment was considered to be fused radiographically in 7 (53%) of the 13 controls and 9 (69%) of the 13 rats treated with RIS (p = 0.851). The mean histological scores were 5.69 +/- 0.13 and 3.84 +/- 0.43 for the control and treatment groups, respectively. There was a significant difference between the both groups (p = 0.001). The mean bone density of the fusion masses was 86.9 +/- 2.34 in the control group and 106.0 +/- 3.54 in the RIS treatment group. There was a statistical difference in mean bone densities of the fusion masses comparing the two groups (p = 0.001). CONCLUSION: In this study, risedronate appears to delay bone fusion in a rat model. This occurs as a result of uncoupling the balanced osteoclastic and osteoblastic activity inherent to bone healing. These findings suggest that a discontinuation of risedronate postoperatively during acute fusion period may be warranted.
Key Words: Rats; Risedronate; Spinal fusion; Spine
Editorial Office
1F, 18, Heolleung-ro 569-gil, Gangnam-gu, Seoul, Republic of Korea
TEL: +82-2-525-7552   FAX: +82-2-525-7554   E-mail: kns61@neurosurgery.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Neurosurgical Society.                 Developed in M2PI
Close layer